Nutrition, the digestive system and immunity in COVID-19 infection

Justine Bold1,2, Miranda Harris1, Lindsey Fellows1, Manal Chouchane1
1School of Allied Health & Community, University of Worcester, Worcester, WR2 6AJ, UK
2Centre for Medical Education, Medical School, Cardiff University, Cardiff, CF14 4YS, UK

ABSTRACT

The current review aimed to synthesize the literature on the complex relationship between food consumption and nutritional status as well as the digestive system in order to examine the relationship between immunity and potential responses to COVID-19 infection. The goal is to help inform the many healthcare professionals working with COVID-19 patients. A literature search was performed on PubMed, Scopus, and EMBASE databases. Hand searches were also undertaken using Google and reference lists to identify recent evidence. Studies were critically appraised, and the findings were analyzed by narrative synthesis. Nutritional status can impact immunity in several ways, including affecting susceptibility to infection, severity of disease, and recovery time, and is therefore a significant consideration in the management of COVID-19. COVID-19 can also impact digestive function, which can further impact nutritional status. The role of Vitamin D deficiency in vulnerability to severe respiratory infections, including COVID-19, has been recognized, and it may have a role in treatment where deficiency is indicated. Healthcare professionals should be aware that obesity may be accompanied by micronutrient malnutrition including vitamin D deficiency and alterations in the microbiome and inflammatory responses, which can further impact immunity and disease severity. Multidisciplinary team-work is recommended in the management of patients with COVID-19, and approaches should include a consideration of nutritional status (both macronutrients and micronutrients), body weight, and gastrointestinal signs and symptom.

Keywords: Obesity, COVID-19, Nutritional status, Vitamin D, Microbiome, Multidisciplinary, Supplementation, Practice.

Introduction

The COVID-19 pandemic is a novel infection and a major global healthcare challenge which highlights the need for cost-effective strategies that both prevent complications and support recovery, reducing recovery times and complications wherever possible. The current review aims to consider the relationship between COVID-19 infection and nutritional status, including obesity, and the broader impact it may have on both digestive function and gastrointestinal (GI) symptoms of COVID-19 infection. It is hoped this will inform all areas of healthcare practice and increase awareness of the importance of considering nutrition in a multidisciplinary approach.

Method and Approach

A narrative approach has been used to synthesize findings from a literature search using search terms such as COVID-19 and nutritional status, obesity, malnutrition, nutritional deficiency, vitamin D, and microbiome. PubMed, Scopus and EMBASE databases were used and hand searches were also undertaken using Google and reference lists to identify recent evidence. Studies were critically appraised, and the findings were analyzed by narrative synthesis.

Malnutrition

The nutritional status of populations is recognized as a key factor influencing resilience against destabilization in the current COVID-19 pandemic (1). Community resilience is generally considered to be the ability to recover from adverse events (2). Malnutrition is an established risk factor for lowered immunity (3), and a hospital stay can increase a patient’s chances of both...
complications and re-admission after discharge (4). Malnutrition can occur in both energy and macronutrient terms (carbohydrates, proteins, fats) and may also occur as micronutrient (vitamins and minerals) deficiency, which can potentially co-exist with obesity, where someone is potentially overfed in terms of energy (Kcal) but deficient in one or more micronutrients. A study published in 2017 reported on data from 1990-2017 and concluded that dietary factors were linked to 11 million deaths and 255 million disability-adjusted life-years across the world in 2017 (5).

Any infection outcome is affected by nutritional status, due to effects on both innate and adaptive immune responses (6). Vitamins B, C, and E alongside iron, selenium, and zinc play a supporting role in immunocompetence (7, 8), and any chronic shortages in these micronutrients may further impair immune function through cell activation and changes in signaling, molecule production, and gene expression (9). It should also be remembered that diet (and particularly components such as fiber) influences gut microbial composition which helps to promote immune responses in the body (10).

**Vitamin D Status**

Vitamin D may protect against the risk of contracting influenza (11), and vitamin D deficiency is associated with a higher risk of community-acquired pneumonia (12) and GI disorders such as inflammatory bowel disease (13). It also seems to be an important factor in other viral respiratory infections. Alipio (14) presented significant data (p<0.001) regarding vitamin D status and the severity of SARS symptoms observed in patients admitted to three hospitals in South Asia. The data indicated that the majority of patients with mild symptoms (n=85.5%) presented with serum OH(D) of 31.2 ng/mmol (normal vitamin D status), with only 3.6% of patients in this category presenting with severe and critical symptoms (14). Vitamin D deficiency is common in people who are housebound and not going outside as vitamin D is synthesized through skin exposure to sunlight. Thus, a population in quarantine or lockdown may experience lowered levels of vitamin D. Moreover, skin pigmentation also affects production levels; skin with more pigmentation will produce less, so deficiency is more common in people with darker skin (15). Debates about whether this is implicated in higher death rates from COVID-19 infection among Black, Asian, and minority ethnic people (16) are gaining momentum. Both obesity and Type 2 diabetes (T2D) are also associated with high rates of vitamin D deficiency (17). It is also known that people with diabetes and obesity are more vulnerable to severe disease with COVID-19 infection. It seems vitamin D deficiency is relatively commonplace, as over a billion people globally are thought to be affected (18). In the UK, a country with high COVID-19 death rates, around a third of adults appear to be deficient in vitamin D. The National Diet and Nutrition Survey analysis of the last 9 years reported that in the UK from January to March, 19% of children aged 4 to 10 years, 37% of children aged 11 to 18 years, and 29% of adults had low Vitamin D levels (25-OHD below 25nmol/L), indicating a risk of

**Stress**

Physical trauma is known to cause injury and dysfunction of the gut as well as increased intestinal permeability (20). Psychological stress also impacts gut dysbiosis and permeability by increasing the corticotropin-releasing hormone and its effect on TNFα (21), as well as other pro-inflammatory cytokines, which is evident in viral infections. The effect of being critically ill may compound an already compromised GI tract, and it is known that gut dysfunction can contribute to multi-organ dysfunction syndrome (20). Other GI mechanisms relevant to the pathophysiology of viral infection include the reduction of butyrate, which helps to maintain the gut barrier and is known for its anti-inflammatory effects, and the elevation of circulating lipopolysaccharides from the increase in gut permeability (22). This leads to the upregulation of inflammatory cytokines, which triggers systemic inflammation (23, 24). The consequential impact on mitochondrial function together with immune system responses further demonstrate the potential effects of COVID-19 on a range of interconnected body systems (25).

**Microbiome and Immunity**

Gut microbiota influences the maturation and development of immune cells such as dendritic cells and T cells, while also regulating the synthesis of the cytokines IL-10 (suppresses Th-1 dominant pro-
inflammatory response) and TGF-β (promotes the development of regulatory T cells) (26). Gut microbiota can also have indirect modulatory effects on inflammation including the production of short chain fatty acids (SCFA) (27) and the promotion of the synthesis of antimicrobial peptides (28). Thus, the interaction between the host’s microbiome and the immune system is complex due to the many pathways by which the microbiota can modulate immune responses to pathogens. 

*Lactobacillus* species specifically have been recognized for their role in stimulating the innate immune response by acting as ligands for Toll-like receptors (TLR) and activating important signaling pathways such as NF-κB, mitogen-activated protein kinase, and peroxisome proliferator-activated receptor gamma, all of which are involved in regulating cellular behaviors such as inflammatory responses (29). Furthermore, other species have been found to produce substances which can cross epithelial cell membranes and bind to intracellular receptors known as nucleotide-binding oligomerization domain receptors (NLRs) (30). NLR activation is responsible for regulating inflammatory responses by acting on the NF-κB and peroxisome proliferator-activated receptor gamma signaling pathways. TLRs and NLRs are associated with activating caspase 1, an enzyme involved in the maturation of the pro-inflammatory cytokines IL-1β and IL-18 (31). Such pro-inflammatory effects have been suggested to serve physiological benefits such as immune system response ‘priming’, which can promote the host’s defense against pathogens (29). 

Decreased microbiome biodiversity resulting from the lack of exposure to microorganisms due to excessive cleanliness (the ‘Hygiene Hypothesis’) (32), increased antibiotic use, and poor diet have been suggested to be major contributing factors in the increasing levels of inflammatory disorders. An imbalance in gut flora can trigger an inflammatory immune response, causing intestinal hyperpermeability, which in turn can trigger a further localized inflammatory response within the gut (33), creating a vicious cycle of inflammatory responses. SARS-Cov-2 causes lung infections by binding to angiotensin-converting enzyme 2 (ACE2) receptors within alveolar epithelial cells which, interestingly, are also expressed within intestinal enterocytes. Furthermore, SARS-Cov2 RNA was reported to be found in the feces of infected individuals (34). These factors along with the fact that microbiome diversity is reduced in older age, and it is the elderly patients who have suffered fatally from COVID-19, clearly indicates a possible link between COVID-19 immune response and gut microbiome.

**COVID-19 GI Symptoms**

Evidence suggests GI symptoms including nausea, loss of appetite, diarrhea and vomiting, and abdominal pain have been added in approximately a third of COVID-19 patients (35-38). More recently, olfactory and gustatory dysfunction have been reported as common symptoms, which may affect appetite (90).

**How the virus enters the cell**

Entry of the coronavirus into the cytoplasm of the host cell is initiated by the attachment of the receptor binding domain of the viral glycoprotein known as the spike (S) protein to the membrane protein ACE2. Transmembrane serine protease (TMPRSS) 2 facilitates entry into the cell by cleaving the S protein. As previously mentioned, ACE2 expression has been detected on the enterocytes of the small intestine, more so on the crypt epithelium and less so on the surface epithelium of the colon (34). TMPRSS2 has been observed on surface and crypt epithelia in the colon but is less obvious in the ileum and only on the crypt epithelium (39).

**Obesity**

Obesity, classified as a body mass index (BMI) > 30kg/m², is recognized as one of the most significant public health problems in the world with approximately two billion overweight men and women (39% of adults aged 18 and over), of which 650 million are obese (40). If current trends of prevalence continue, 2.7 billion adults will be overweight by 2025, and one billion of these will be obese (40). One possible explanation of the virulence factor for COVID-19 in obesity and adverse outcomes is the rising issue of micronutrient and protein deficiency resulting from a monotonous diet often seen in a medical condition known as sarcopenic obesity, where low muscle mass and obesity coexist (41). Not only is there an increase in low-grade systemic inflammation due to excess adipose tissue, but the direct effect of vitamin deficiency such as A and D can lead to compromised functioning of antibody-
secretory cells (42) and T-cell proliferation (43), respectively.

**Obesity as a Risk Factor for Severe Disease in COVID-19**

Obesity has been identified by the World Health Organization as a serious risk factor for COVID-19 outcomes and for poor adverse outcomes for COVID-19 (44). Increasing risks have been associated with increasing BMI (45). In a New York hospital cohort study (n=3615), obesity was cited as a risk factor for treatment escalation (46) and for admission to intensive care units (ICU) in the United Kingdom (UK). A study by the UK Intensive Care National Audit and Research Centre reported that over 73% of those in ICUs were overweight or obese (34.6% and 38.5%, respectively) (47). Obesity was recognized as a risk factor for inhospital mortality after adjusting for other comorbidities in an observational, prospective cohort study in the UK (n=16,749) (48).

Although obesity is associated with severe forms of COVID-19, the prevalence of severe obesity (BMI >35kg/m²) reported in ICUs may reflect the local prevalence of obesity as seen in two seminal studies in France, one in Lille, where the prevalence was reported as 28.2% (45), and one in Lyon, where the prevalence was 11.3%. The requirement for invasive mechanical ventilation (IMV) compared to lean subjects reflected these differences with 68.6% and 58.4%, respectively. In a retrospective cohort study, obesity prevalence was high among ICU patients (44), and in other research, patients with a BMI between 30-34.9kg/m² were 1.8 times more likely than those with a BMI <30kg/m² to be admitted to the ICU (46). This is more of an issue in the USA and UK (countries which have high mortality rates in the current pandemic) because of the high prevalence of obesity (42% and 29%, respectively) (49, 50).

Obesity is a risk factor for impaired metabolic function, such as insulin resistance and T2D (51). The metabolic effect of excessive fat may result in reduced pancreatic beta cell performance, which may be compounded by the direct effect of COVID-19 on function (52). Inflammation of adipose tissue results in other metabolic dysfunctions such as dyslipidemia, hypertension, and cardiovascular disease (CVD) (51, 53). Although comorbidities for obesity such as heart and lung disease, hypertension, and T2D may confound results, severe obesity has been associated with ICU admissions and obesity associated with the use of IMV (both reaching statistical significance) (54).

**Obesity and Immune Function**

Obesity may predispose adults to impaired immune function and increased susceptibility to infection (51). Multiple factors are implicated, such as chronic inflammatory status, delayed immune response, and the complex relationships and interactions between adipose tissue and the immune system (55). High levels of ACE2-expressing cells are found in adipose tissue, and because obese individuals have more adipose tissue, this could elucidate that they have a greater amount of ACE2. COVID-19 has an enhanced affinity for ACE2 (53), which is a supposed receptor for the entry of COVID-19 into host cells (56). Adipose tissue may contribute to the progression of COVID-19 by other mechanisms, including the imbalance between anti-and pro-inflammatory cytokines, particularly adipokines; overexpression of the latter may lead to aberrant chemotaxis and abnormal macrophage differentiation, further compromising immune function (55). Other innate responses associated with obesity lead to the excessive release of pro-inflammatory cytokines such as IL-6 (55), TNFα, IFNγ, and IL-2 and higher levels of circulating C-reactive protein (53). Elevated IL-6 levels have been correlated with ICU admission, respiratory failure, and adverse outcomes (39).

**Obesity and the Microbiota**

Studies have shown that obesity is associated with changes in the assortment of microorganisms inhabiting the GI tract, which include viral, fungal, bacterial, and single-celled microorganisms called areaea, collectively known as the gut microbiota, and that obese adults have less diversity and richness in the bacterial composition (57-59). As previously mentioned, gut bacteria play a vital role in protection against pathogenic microorganisms, immune modulation, and other functions such as digestion and metabolism and SCFA production (60-62).

*Firmicutes* and *Bacteroidetes* make up approximately 90% of the total microorganisms with some research reporting an increased ratio of *Firmicutes* to *Bacteroidetes* in the feces of obese subjects (57, 63,
64); however, a systematic review was equivocal in its overview of the association between BMI and microbiota (65) with some studies supporting this theory and others finding no association, although this may be explained by differing methodological approaches.

Recent evidence suggests the presence of microorganisms such as *Bacteroidetes*, *Firmicutes*, and *Proteobacteria* in the lungs and that a bidirectional relationship exists between the lungs and the gut (66). Dysbiosis, which results from a lack of gut diversity, has been associated with many diseases, including acute respiratory distress syndrome and sepsis (67).

### 2.4. Obesity and Dietary Habits

Obesity is affected by unhealthy eating habits, as seen in a cross-sectional study (n=1557) that looked at the association of abdominal obesity with food inadequacy and physical activity (68). They reported a lower likelihood of abdominal adiposity in those who consumed a minimum of three portions of fruit a day and did not exceed the upper limit of saturated fat (35% and 28%, respectively). Furthermore, in data from a longitudinal study n=50, improvements were found in weight, body fat, and waist circumference on a diet of fruits, vegetables, and grains containing 30g fiber/day compared to controls (69). Normal weight adults (n=52) consumed 43% more complex carbohydrates and 33% more fiber than overweight/obese adults when matched for gender, age, and physical activity (77).

Diets that include high fat and low fiber can impact the diversity of the human gut microbiota, even over a few days (70). Conversely, a fiber-rich diet may have a positive effect on the gut microbiota and improve both metabolic and immune markers; for example, non-digestible carbohydrates such as whole grains may reduce pro-inflammatory cytokine IL-6 and insulin resistance (71). Interestingly, switching from a Western style diet of high fat/high sugar refined carbohydrates to a low-fat diet rich in plant-poly saccharides may influence the composition of microbiota, once again within a relatively short time, this time to the benefit of the microbiota (42). In addition, probiotics found in fermented foods may further reduce inflammation and help to regulate innate immunity (72). Anti-inflammatory marker IL-10 may be increased through the intake of prebiotics, increasing the production of SCFAs and improving the health of the GI-associated lymphoid tissue. Not only gut microbiota, but also lung microbiota is improved, thus offering a potential strategy for improving clinical outcomes of COVID-19 (41).

### Melatonin

Melatonin, released by the pineal gland at nighttime, has long been associated with the adjustment of the circadian phase to the environment, known as circadian rhythm entrainment; however, it also has antioxidant and anti-inflammatory properties, the latter due to its close relationship with mitochondrial function (73). The melatonergic pathway, which starts with the conversion of tryptophan to serotonin, then to N-acetylserotonin, and finally to melatonin, has created some interest due to its interaction with COVID-19 and other viruses (25). Elevated levels of stress may affect the availability of tryptophan for the melatonergic pathway, thus causing circadian (74, 75) and mitochondrial dysregulation (76). Pre-existing medical conditions mentioned previously have been linked to both of these regulatory mechanisms as well as to gut dysbiosis and increased gut permeability.

### Supportive Nutritional Interventions

**Multidisciplinary Team Practice**

This review has indicated clear links between nutrition status (specifically micronutrient insufficiency and deficiency), compromised gut function, and the effects of obesity on viral severity, including SARS, CAP, and now COVID-19. Hence, a multidisciplinary approach is likely to be of benefit in terms of patient outcomes.

Health services should adapt to prioritize reducing obesity and weight loss in general, given the inverse correlation between obesity/excess weight and COVID-19 severity. In response to this, the UK government launched an obesity strategy, labeled the COVID-19 ‘wake-up-call’, in July 2020 (81). The preventative strategies outlined include general practitioners being incentivized to prescribe activity and exercise to enhance physical fitness and primary care healthcare staff being trained as ‘healthy weight coaches’ to provide more specialist support to those in need (81). Allied health professionals with nutrition expertise such as dieticians, nutritionists, and nutritional therapists may also have a role in supporting individuals in their recovery from COVID-19 or in advising those seeking preventative or ‘prehabilitation’ healthy eating advice.
or supplement regimes (85). They can also help support individuals with weight loss. Ostensibly, these nutrition professionals will be required to assess the nutritional status and check drug-nutrient interactions of individuals in the first instance, before they provide safe guidance on nutritional supplementation. Since the start of the pandemic, claims, often unfounded and unsafe, of how specific foods and herbs may provide protection from COVID-19 have been circulating via social media (1). Thus, nutrition professionals have the added responsibility of dispelling any myths spread during the pandemic and ensuring safe intake of immune supporting nutrients (1).

**Nutritional supplementation as Adjunct Treatment in COVID-19**

In supporting patients with COVID-19, vitamin D has the potential to be used as an adjunct treatment to medication. A variety of doses have been used to treat SARS and CAP to date, with therapeutic applications ranging from 30-2500 μg/d (77, 78). Indeed, the results of a study currently ongoing at University Hospital, Angers (France), with COVID-19 patients ≥70 years of age are awaited. The hypothesis seeks to prove that high dose (2 x 2000,000 IU/d or 2 x 5 mg/d) vitamin D is more effective on improved prognosis when compared to a standard dose (50,000IU/d or 125 μg/d).

Evidence also exists in support of the probiotic *Lactobacillus Rhamanous*, which can be given as an oral supplement, and its efficacy in helping patients avoid being ventilated as well as in treating viral respiratory infection. *Bifidobacterium* appears to improve immune function and intestinal microbiota (79, 80). Both strains support further consideration for adjunct treatments in addressing possible dysbiosis and improving microbiome diversity.

Vitamin C is known to be immunomodulatory. Moreover, antimicrobial and high-dose intravenous vitamin C is being researched for its potential in blocking the cytokine storm associated with COVID-19 infection (91).

**Preventative Nutritional Intake and Supplementation for the General Population**

The debate regarding standardized, population-wide supplementation is ongoing, and the COVID-19 pandemic has certainly raised more questions around this topic. For example, the current UK recommendations for vitamin D supplementation of 10 μg/d are based on the role of vitamin D in bone health and calcium metabolism and do not take into account its role in immune regulation (82). Furthermore, this recommendation is for everyone aged 1 and older (8.5 μg/d birth to 1 year), with supplementation recommended in the winter months when sunlight is reduced. While not discounting the potential risks associated with higher intakes of vitamin D (83), this review has presented evidence linking the impact of modern day life, e.g., poor eating habits, stress, lack of microbiome diversity, and being overweight or obese, to nutritional insufficiency.

Indeed, it is apparent that levels of micronutrient intake above those set by public health bodies (such as the RDA in the USA or the RNI in the UK) are required to support optimal function of the immune system, with recommendations for supplementation of vitamin D to be above the RDA (84). Similarly, this implication can be made to vitamin C, with the current UK RNI for adults being 40 mg/day (set at a level to prevent deficiency in the majority 97.5% of the population) (86). Vitamin C deficiency is linked to severe respiratory tract infections and overall disease severity, and plasma levels are known to be affected by infection.

**Table 1.** Recommended intakes of vitamins D and C to support optimal immunity for the wider population.

| Nutrient   | Justification                                                                                                                                  | Recommendation                                                |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Vitamin D  | Revision of the current UK guidelines is advocated (82). 10 μg/d is not sufficient for individuals in at-risk groups at any time (82).        | Daily intake of 50 μg/d (84, 85)                               |
|            | 10 μg/d is not sufficient for individuals between October-April in cold, Northern Hemisphere countries (77).                               | [Daily intake of 50-125 μg/d has been advised dependent on age, risk, and time of year (11).] |
| Vitamin C  | 40 mg/d is not sufficient for UK adults (86). EU guidance for adults is 95 mg/d (87). Higher daily doses (≥200mg/d) are required for optimal immune function (84). | Daily intake of 200 mg/d (84)                                  | [Daily intake of 1-2 g/d for individuals who are unwell (84)] |
(84). The UK RNI is significantly less than guidance in other countries, and new evidence is emerging to optimally support immune function (84, 87). Table 1 outlines a summary of the recommendations for supplementation of vitamins D and C based on current evidence.

**Conflict of interests**

The authors declare that they have no conflict of interest.

**References**

1. Naja F, Hamadeh R. Nutrition amid the COVID-19 pandemic: a multi-level framework for action. Eur J Clin Nutr 2020;1-5.

2. Castleden M, McKee M, Murray V, Leonardi G. Resilience thinking in health protection. J Public Health 2011;33:369-77.

3. British Dietetic Association (BDA). Malnutrition Food Fact sheet. Available from: https://www.bda.uk.com/resource/malnutrition.html.

4. Frank M, Sivagnanaratnam A, Bernstein J. Nutritional assessment in elderly care: a MUST! BMJ Open Qual 2015;4:u204810.w2031.

5. GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2019;393:1958-72.

6. Alwarawrah Y, Kiernan K, MacIver NJ. Changes in nutritional status impact immune cell metabolism and function. Front Immunol 2018;9:1055.

7. Gombar AF, Pierre A, Maggini S. A review of micronutrients and the immune system-working in harmony to reduce the risk of infection. Nutrients 2020;12:236.

8. Gleeson M, Nieman DC, Pedersen BK. Exercise, nutrition and immune function. J Sports Sci 2004;22:115-25.

9. Valdés-Ramos R, Martínez-Carrillo BE, Aranda-González II, Gua- darrama AL, Pardo-Morales RV, Tlatempa P, et al. Diet, exercise and gut mucosal immunity. Proc Nutr Soc 2010;69:644-50.

10. Wypych TP, Marsland BJ, Ubags ND. The impact of diet on immunity and respiratory diseases. Ann Am Thorac Soc 2017;14:S339-47.

11. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French ChB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients 2020;12:988.

12. Zhou YF, Luo BA, Qin LL. The association between vitamin D deficiency and community-acquired pneumonia: A meta-analysis of observational studies. Medicine 2019; 98:e17252.

13. Frigstad SO, Hoivik ML, Jahnson J, Cvancarova M, Grimstad T, Berset IP, et al. Pain Severity and Vitamin D Deficiency in IBD Patients. Nutrients 2019;12:26.

14. Alipio M. Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19). 2020.

15. Richard A, Rohrmann S, Quack Lötischer KC. Prevalence of Vitamin D Deficiency and Its Associations with Skin Color in Pregnant Women in the First Trimester in a Sample from Switzerland. Nutrients 2017;9:260.

16. Kamlesh K, Kumar SA, Manish P, Wasim H. Is ethnicity linked to incidence or outcomes of covid-19? BMJ 2020;369:m1548.

17. Via M. The Malnutrition of Obesity: Micronutrient Deficiencies That Promote Diabetes. ISRN Endocrinol 2012;2012:103472.

18. Nair R, Maseeh A. Vitamin D: The "sunshine" vitamin. J Pharmacol Pharmacother 2012; 3:118-26.

19. British Nutrition Foundation (BNF) NDNS: time trend and income analyses for Years 1 to 9. Available from: https://www.gov.uk/government/statistics/ndns-time-trend-and-income-analyses-for-years-1-to-9.

20. Patel JJ, Rosenthal MD, Miller KR, Martindale RG. The gut in trauma. Curr Opin Crit Care 2016; 22:339-46.

21. Vanuysel T, van Wanrooy S, Vanheel H, Vanormalinger C, Verschueren S, Houben E, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014;63:1293-9.

22. Anderson G. Gut dysbiosis dysregulates central and systemic homeostasis via decreased melatonin and suboptimal mitochondria functioning: pathoetiological and pathophysiological implications. Melatonin Research 2019;2:70-85.

23. Al-Assal K, Martinez A, Torrinhas R, Cardinelli, Waitzberg D. Gut Microbiota and Obesity. Clin Nutr Exp 2018;60-4.

24. Tseng AH, Wu CY. The Gut Microbiome in Obesity. J Formos Med Assoc 2019;118:S3-9.
25. Anderson G, Reiter RJ. Melatonin: Roles in influenza, COVID-19 and other viral infections. Rev Med Virol 2020;e2109.
26. Bermudez-Brito M, Plaza-Diaz J, Munoz-Quezada S, Gomez-Llorente C, Gil A. Probiotic Mechanisms of Action. Ann Nutr Metab 2012;61:160-74.
27. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by Short Chain Fatty Acids. Nutrients 2011;3:858-76.
28. Schlee M, Harder J, Koten B, Stange EF, Wehkamp J, Fellenkam K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 2008;151:528-35.
29. Lescheid DW. Probiotics as regulators of inflammation: A review. Funct Foods Health Dis 2014;4:299-311.
30. Thomas CM, Versalovic J. Probiotics-host communication. Modulation of signaling pathways in the intestine. Gut Microbes 2010;1:148-63.
31. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-32.
32. Doré J, Simré M, Buttle L, Guarner F. Hot topics in gut microbiota. United Europ Gastroenterol J 2013;1:311-8.
33. Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol 2008;8:435-46.
34. Dhar D, Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus Res 2020;285:198018.
35. Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv 2020.
36. Jin X, Lian JS, Hu JH, Gao J, Zheng Y, Hao S, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69:1002-9.
37. Tian Y, Rong L, Nian W, Yan H. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020;51:843-51.
38. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;20.
39. Suárez-Fariñas M, Tokuyama M, Wei G, Huang R, Livanos A, Jha D, et al. Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease. Gastroenterology 2020;S0016-5085:35210-0.
40. WHO. Obesity and overweight Key Facts 2020. Available online at https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Accessed at: June 8, 2020]
41. Davis C. The Gut Microbiome and Its Role in Obesity. Nutr Today 2016;51:167-74.
42. Shirakawa AK, Nagakubo D, Hishima K, Nakayama T, Jin Z, Yoshie O. 1,25-dihydroxyvitamin D3 induces CCR10 expression in terminally differentiating human B cells. J Immunol 2008;180:2786-95.
43. Ertesvag A, Engedal N, Naderi S, Blomhoff HK. Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion. J Immunol 2002;169:5555-63.
44. Simonnet A, Chetboun M, Poissy J, Raverdy, V Noullette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity 2020;28:7.
45. Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv 2020.
46. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois. et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis 2020;71:896-7.
47. ICNARC Report on COVID-19 in critical care 2020. Available online at https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports [Accessed June 8 2020]
48. Docherty A, Harrison E, Green, Hardwick H, Pius R, Norman L, et al. (2020). Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. BMJ 2020;369:m1985.
49. Centres for Disease Control and Prevention. Obesity is a Common, serious and costly disease 2020. Available online at https://www.cdc.gov/obesity/data/adult.html [Accessed June 8 2020]
50. NHS Digital. Statistics on Obesity, Physical Activity and Diet England 2019. Available online at https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-
obesity-physical-activity-and-diet/statistics-on-obesity-physical-activity-and-diet-england-2019 [Accessed June 8 2020]

51. Stefan N, Birkenfeld A, Schulze M, Ludwig D. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol 2020;16:341-2.

52. Sattar N, McInnes I, McMurray J. Obesity is a Risk Factor for Severe COVID-19 Infection Multiple Potential Mechanisms Circulation 2020;142:1.

53. Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev 2020;21:e13034.

54. Kalligeros M, Shehadeh F, Evangelia K, Benitez G, Beckwith C, Chan P, et al. Association of Obesity with Disease Severity among Patients with COVID-19. Obesity 2020;28:7.

55. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes 2013;37:333-40.

56. Zhou P, Yang X, Shi Z. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.

57. Ley RE, Turnbaugh PJ, Klein S, Gordon JL. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022e3.

58. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013;500:541e6.

59. Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J 2013;13:514e22.

60. Lang JM, Eisen JA, Zivkovic AM. The microbes we eat: abundance and taxonomy of microbes consumed in a day's worth of meals for three diet types. Peer J Computer Science 2014;2:e659.

61. Kaplan JL, Walker WA. Early gut colonization and subsequent obesity risk. Curr Opin Clin Nutr Metab Care 2012;15:278e84.

62. Aziz Q, Dore J, Emmanuel A, Guarner F, Quigley EM. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil 2013;25:e15.

63. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010;59:3049e57.

64. Kong LC, Tap J, Aron-Wisnewsky J, Pelloux V, Basdevant A, Bouillot JL, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr 2013;98:16e24.

65. Castaner O, Goday A, Park YM, Lee SH, Magkos F, Shiow S, et al. The Gut Microbiome Profile in Obesity: A systematic review. Int J Endocrinol 2018;2018:4095789.

66. Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. The role of the lung microbiota and the gut–lung axis in respiratory infectious diseases’. Cell Microbiol 2018;20:e12966.

67. Groves H, Higham S, Moffatt M, Cox M, Tregoning. Respiratory viral infection alters the gut microbiota by inducing inappetence. mBio 2020;11:1-17.

68. Burini C, Kano H, Nakagaki M, Frenhani P, Portero-McLellan. Behavioural factors of Abdominal Obesity and effects of lifestyle changes with Fiber Adequacy. New Insights in Obesity: Genetics and Beyond 2017;1:014-022.

69. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011;334:105e8.

70. Keim NL, Martin RJ. Dietary Whole Grain–Microbiota Interactions: Insights into Mechanisms for Human Health, Adv Nutr 2014;5:556-7.

71. West N, Christophersen C, Pyne D, Cripps A, Conlon M, Topping D, et al. Butyrylated starch increases colonic butyrate concentration but has limited effects on immunity in healthy physically active individuals. Exerc Immunol Rev 2013;102.

72. Tan DX, Reiter RJ. Mitochondria: the birthplace, battleground and the site of melatonin metabolism in cells. Melatonin Res 2019;2:44-66.

73. Chellappa SL, Vujovic N, Williams JS, Scheer FAJL. Impact of circadian disruption on cardiovascular function and disease. Trends Endocrinol Metab 2019;30:767-79.

74. Truong KK, Lam MT, Grandner MA, Sassoon CS, Malhotra A. Timing matters: circadian rhythm in sepsis, obstructive lung disease, obstructive sleep apnea and cancer. Ann Am Thorac Soc 2016;13:1144-54.

75. Geto Z, Molla MD, Challa F, Belay Y, Getahun T. Mitochondrial dynamic dysfunction as a main triggering factor for inflammation associated chronic
non-communicable diseases. J Inflamm Res 2020;13:97-107.

76. Davis J, Hodges V, Gillham B. Normal-Weight Adults Consume More Fiber and Fruit than Their Age- and Height-Matched Overweight/Obese Counterparts. J Amer Diet Assoc 2006; 106:6.

77. Brown B. Vitamin D and COVID-19: ignoring the evidence costs lives. Integrative Healthcare and Applied Nutrition 2020;10-14.

78. McCartney DM, Byrne DG. Optimisation of vitamin D status for enhanced Immuno-protection against Covid-19. Ir Med J 2020;113:58.

79. Mak JW, Chan FK, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol 2020;5:644-5.

80. Jayawardena R, Sooriyarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. Diabetes Metab Syndr 2020;14:367-82.

81. GOV.UK. Tackling Obesity: Empowering Adults and Children to lead healthier lives (Policy Paper). 2020. Available from: https://www.gov.uk/government/publications/tackling-obesity-government-strategy/tackling-obesity-empowering-adults-and-children-to-live-healthier-lives (Accessed: 04/08/20)

82. SACN. Vitamin D and Health Report. 2016. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/537616/SACN_Vitamin_D_and_Health_report.pdf (Accessed: 01/05/20)

83. Lanham-New SA, Webb AR, Cashman KD, Buttriss JL, Fallowfield JL, Masud T, et al. Vitamin D and SARS-CoV-2 virus/COVID-19 disease. BMJ Nutrition Prevention Health 2020;0.

84. Calder PC, Carr AC, Gomburt AF, Eggersdorfer M. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients 2020;12:1181.

85. Derbyshire E, Delange, J. COVID-19: is there a role for immunonutrition, particularly in the over 65s? BMJ Nutrition, Prevention & Health 2020;0:1-6.

86. Committee on Medical Aspects of Food Policy. Dietary Reference Values for food energy and nutrients for the United Kingdom. London: Stationery Office Books; 1991.

87. Gibney M, Lanham-New S, Cassidy A, and Vorster H. An Introduction to Human Nutrition. 2nd edition. Oxford, Wiley-Blackwell 2009. British J Nutr 2009;102:1387.

88. Mehrbod P, Amini E, Tavassoti-Kheiri M. Antiviral activity of garlic extract on influenza virus. Iran J Virol 2009;3:19-23.

89. Panyod S, Ho CT, Sheen LY. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. J Tradit Complement Med 2020;10:420-7.

90. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg 2020;163:3-11.

91. Liu F, Zhu Y, Zhang J, Li Y, Peng Zh. Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. BMJ Open 2020; 10:e039519.